Clinical Trial Update: Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating drug interaction between vildagliptin (LAF237) and voglibose in Japanese patients with Type 2 Diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Voglibose (voglibose)
• vildagliptin (LAF237) (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED